Uniquity Bio, a clinical-stage drug development company backed by Blackstone Life Sciences, has appointed Will Kane as its new President and Chief Executive Officer. The announcement follows the departure of co-founder and former CEO Brian Lortie in June 2025. The
Merck, known as MSD outside the United States and Canada, has announced a definitive agreement to acquire Verona Pharma plc for $107 per American Depository Share, representing a total transaction value of approximately $10 billion. The move strengthens Merck’s cardio-pulmonary
Circio Holding ASA, a biotechnology company focused on circular RNA technology, has expanded its laboratory operations in Stockholm, Sweden. The new facility at Novum Labs will support the company’s advancing circVec RNA platform, particularly in gene and cell therapy applications.
Orano Med, a subsidiary of the Orano Group and a developer of vector-guided internal radiotherapy (VIR), has announced the completion of a major expansion to its research and development centre in Plano, Texas. The expansion adds around 1,000 m² to
64x Bio, a biotechnology company focused on scalable manufacturing solutions for advanced therapies, has announced the launch of its AAV Apex Suite. The new product line is designed to address critical manufacturing challenges in gene therapy by increasing viral vector
Debiopharm, a Swiss biopharmaceutical company, has signed a co-research agreement with US-based Alkyon Therapeutics to evaluate the development of precision-targeted radioligand therapies (RLTs). The collaboration will combine Debiopharm’s proprietary AbYlink™ conjugation technology with Alkyon’s modular antibody platform targeting undisclosed tumour-associated antigens. The
Medicovestor, a biotechnology company based in New York, has entered into a strategic partnership with Sanyou Biopharmaceuticals, a Shanghai-based biologics specialist. The partnership, signed on 6 June, aims to jointly develop first-in-class chemoimmunotherapy antibody-drug conjugates (ADCs) targeting cancer and autoimmune diseases.
Scinai Immunotherapeutics Ltd. has received regulatory clearance from the Italian government to proceed with its option to acquire Pincell S.r.l., an Italian biotechnology company. The approval falls under Italy’s Golden Power regulation (Law Decree No. 21/2012), which allows the government to
bitBiome, a biotechnology company focused on microbial discovery, has announced a new partnership enabling commercial-scale production of enzymes, proteins, and ingredients. The collaboration establishes bitBiome as a fully integrated organisation, offering services from early discovery through to manufacturing and supply.
Dutch clinical-stage biotechnology company Leyden Laboratories B.V. has secured €20 million in financing from the European Investment Bank (EIB) to accelerate the development of its pan-influenza nasal spray and other antibody-based respiratory therapies. The funding aims to bolster Europe’s readiness against seasonal
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
